A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC)
This is a multi-center observational study in subjects with a diagnosis of small cell lung cancer. Screening and/or medical record review for symptoms associated with Lambert Eaton Myasthenic Syndrome (LEMS) will be conducted.
Checked against the public recordLast updated Aug 4, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Addario Lung Cancer Medical Institute
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1. Adult men or women meeting Age of Majority (AOM) at the time of consent 2. Provide voluntary consent to participate in this study, documented via a signed informed Consent Form (ICF) 3. Any diagnosis of SCLC 4. Willing to provide clinical and medical information related to his/her cancer diagnoses to the study team as required 5. Willing to comply with the requirements of the study Exclusion Criteria: 1. Has been diagnosed with non-tumor Lamber-Eaton Myasthenic syndrome (LEMS) \> 1 year prior to the SCLC diagnosis. 2. Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Dana-Farber Cancer InstituteBoston, Massachusetts
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 4, 2026. Always confirm current availability with the study team.